KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Finished Goods (2017 - 2021)

Historic Finished Goods for Aquestive Therapeutics (AQST) over the last 5 years, with Q1 2021 value amounting to $1.0 million.

  • Aquestive Therapeutics' Finished Goods rose 4279.6% to $1.0 million in Q1 2021 from the same period last year, while for Mar 2021 it was $1.0 million, marking a year-over-year increase of 4279.6%. This contributed to the annual value of $544000.0 for FY2020, which is 481.7% up from last year.
  • Latest data reveals that Aquestive Therapeutics reported Finished Goods of $1.0 million as of Q1 2021, which was up 4279.6% from $544000.0 recorded in Q4 2020.
  • Over the past 5 years, Aquestive Therapeutics' Finished Goods peaked at $1.3 million during Q2 2018, and registered a low of $519000.0 during Q4 2019.
  • Moreover, its 5-year median value for Finished Goods was $1.0 million (2019), whereas its average is $958461.5.
  • In the last 5 years, Aquestive Therapeutics' Finished Goods plummeted by 5612.85% in 2019 and then skyrocketed by 4279.6% in 2021.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Finished Goods stood at $1.1 million in 2017, then rose by 11.18% to $1.2 million in 2018, then crashed by 56.13% to $519000.0 in 2019, then rose by 4.82% to $544000.0 in 2020, then surged by 84.01% to $1.0 million in 2021.
  • Its last three reported values are $1.0 million in Q1 2021, $544000.0 for Q4 2020, and $858000.0 during Q3 2020.